Myriad gains option to acquire rheumatoid arthritis Dx firm
This article was originally published in Clinica
Executive Summary
Myriad Genetics has loaned $25m to Crescendo Bioscience, a venture-backed molecular diagnostics company focused on rheumatology, as part of a bigger deal that could see Myriad acquiring Crescendo outright.